Stock info Oxurion | Filter  Basic-Info

Oxurion (the former Thrombogenics) is a Belgium based biopharmaceutical conglomerate engaged in the production of therapeutic medications for the treatment of ophthalmology, oncology and vascular disorders of the body. The company was founded in 1985 by Professor Desire Collen and KULeuven, as a controlling unit for many of the auxiliary units involving Producell Biotech, Thromb-X and Irish Oxurion Limited, for combining all of them. The company has a working strength of around 100 with Patrik De Haes as its Chief Executive Officer. The company has been headquartered in Leuven, Belgium and the offices of it are also located in the US and Ireland.

The trading of the company is being carried out on the stock exchange of Euronext Brussels with the amount of assets as around 145 million as according to the data 2011, with an overall loss of the company of around 21 million in the same year.

The company has been devoted mainly for the production and commercialization of the pharmacological medications for addressing the problems and therapies in the fields of eyes, heart and cancer. JETREA or ocriplasmin is the leading product of the company, developed for treating VMA (Vitreo Macular Adhesion), launched in this year in January and got approved by the United States Food and Drug Administration. Development of the medication for visual and cardio-vascular disorders along with cancer, resulting mainly from the irregularity of the vascular system of the body, is one of the main focuses of the company.

Oxurion and BioInvent International are the two main bodies involved in the development of one new antibody named as ‘TB-403’ or ‘PlGF i.e. placental growth factor’, as one of the indicating factors of the related responses of oncology and ophthalmology. The company had also been involved in the planned partnership with Alcon or Novartis, for the promotion of JETREA, the happening of 2012. Rhein Minapharm in Egypt and Middle East, Bharat Biotech International Limited in India, BioInvent International AB in Sweden, Millipore Corporation in US, and Alcon situated in Switzerland are the main partners of the company and treated as its alliances.

There are many of the agreements of the company that have been done with many of the reputed and knowledgeable research and academic institutions having a lot of expertise in the same field of ophthalmology, oncology and vascular systems. Flanders Institute for Biotechnology or VIB and Scientific Advisory Boards involved in the programs like the Anti PlGF, Anti Factor VIII, Microplasmin Stroke, and Microplasmin Vitreoretinal are among some of the mainly collaborating institutions.